# PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)

> **NCT06430736** · PHASE2 · RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 100 (estimated)

## Conditions studied

- Myeloma
- Lymphoma
- Leukemia

## Interventions

- **DRUG:** Tocilizumab before CAR-T cell infusion
- **DRUG:** Tocilizumab at emerging CRS

## Key facts

- **NCT ID:** NCT06430736
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06430736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06430736, "PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06430736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*